En español
NIDA

Menu

Randomized Controlled Trial of Osmotic-Release Methylphenidate (OROS-MPH) for Attention Deficit Hyperactivity Disorder in Adolescents with Substance Use Disorders

ADHD in Adolescent Substance Abusers cover

The primary objectives of this study were to evaluate the efficacy of OROS-MPH (Concerta), relative to placebo, in treating ADHD and decreasing substance use in adolescents with ADHD and a substance use disorder. The study involved 303 participants, recruited from 11 community treatment sites.

CTN Protocol ID: 
CTN-0028
DSMB ID: 
DSMB-0028
Enrollment Status: 
Completed
ClinicalTrials.gov ID: 
Primary Outcomes Article: 

Riggs, P., et al. (2011).  Randomized controlled trial of osmotic-release methylphenidate with cognitive-behavioral therapy in adolescents with attention-deficit/hyperactivity disorder and substance use disorders.  Journal of the American Academy of Child & Adolescent Psychiatry 50(9):903-14.
http://www.ncbi.nlm.nih.gov/pubmed/21871372

Principal Investigator(s)
Paula Riggs, M.D.
University of Colorado School of Medicine
paula.riggs@ucdenver.edu

Theresa Winhusen, Ph.D.
University of Cincinnati
Addiction Sciences Division
3131 Harvey Avenue, Suite 104
Cincinnati, OH 45229-3006
winhust@ucmail.uc.edu

Available Brochures

Get this Publication

    Blending Initiative

    blending logo

    Formed with SAMHSA to reduce the gap between research results and treatment.